

## Product datasheet for **TL320276V**

### **B Raf (BRAF) Human shRNA Lentiviral Particle (Locus ID 673)**

#### **Product data:**

Product Type:	shRNA Lentiviral Particles
Product Name:	B Raf (BRAF) Human shRNA Lentiviral Particle (Locus ID 673)
Locus ID:	673
Synonyms:	B-raf; B-RAF1; BRAF1; NS7; RAFB1
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	BRAF - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10 <sup>7</sup> TU/ml.
RefSeq:	<a href="#">NM_004333</a> , <a href="#">NM_001354609</a> , <a href="#">NR_148928</a> , <a href="#">NM_004333.1</a> , <a href="#">NM_004333.2</a> , <a href="#">NM_004333.3</a> , <a href="#">NM_004333.4</a> , <a href="#">BC101757</a> , <a href="#">BC101757.1</a> , <a href="#">BC038966</a> , <a href="#">BC112079</a> , <a href="#">BM263585</a> , <a href="#">NM_004333.6</a>
UniProt ID:	<a href="#">P15056</a>
Summary:	This gene encodes a protein belonging to the RAF family of serine/threonine protein kinases. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which affects cell division, differentiation, and secretion. Mutations in this gene, most commonly the V600E mutation, are the most frequently identified cancer-causing mutations in melanoma, and have been identified in various other cancers as well, including non-Hodgkin lymphoma, colorectal cancer, thyroid carcinoma, non-small cell lung carcinoma, hairy cell leukemia and adenocarcinoma of lung. Mutations in this gene are also associated with cardiofaciocutaneous, Noonan, and Costello syndromes, which exhibit overlapping phenotypes. A pseudogene of this gene has been identified on the X chromosome. [provided by RefSeq, Aug 2017]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact <a href="mailto:techsupport@origene.com">techsupport@origene.com</a> . If you need a special design or shRNA sequence, please utilize our <a href="#">custom shRNA service</a> .



[View online »](#)

**Performance  
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at [techsupport@origene.com](mailto:techsupport@origene.com). Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).